Clinical trials: Select Advanced Malignancies
Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer.
- Trial name
- NCT04974957
- Testing
- SHR-1701；BP102
- Volunteers
- 71 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Solid Tumor, Adult
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects…
- Trial name
- Zotatifin (NCT04092673)
- Testing
- eFT226, Sotorasib, Fulvestrant
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- Effector Therapeutics
Advanced Solid Tumors
A Study of BG-C477 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected…
- Trial name
- NCT06596473
- Testing
- BG-C477, Tislelizumab, Chemotherapy
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 310 people
- Sponsor
- BeOne Medicines
Endometrial Cancer, Endometrial Cancer Recurrent
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab…
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer
- Trial name
- NCT02922764
- Testing
- RGX-104, Ipilimumab, Docetaxel
- Where
- 21 sites in United States
- Volunteers
- 146 people
- Sponsor
- Inspirna, Inc.
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with…
- Trial name
- NCT05306340
- Testing
- Giredestrant, Exemestane, Fulvestrant
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 373 people
- Sponsor
- Genentech, Inc.
Endometrial Adenocarcinomas, Neuroendocrine Tumors
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose…
- Conditions
- Endometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
- Trial name
- NCT01970540
- Testing
- lurbinectedin (PM01183), Doxorubicin
- Where
- 7 sites in Spain, United Kingdom
- Volunteers
- 122 people
- Sponsor
- PharmaMar
Colorectal Cancer
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in patients with advanced colorectal cancer who have HER2 IHC3+ and have failed prior…
- Trial name
- NCT07730489
- Testing
- BL-M07D1, Regorafenib, Fruquintinib
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Urothelial Cancer
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who…
- Trial name
- THOR (NCT03390504)
- Testing
- Erdafitinib, Vinflunine, Docetaxel
- Where
- 345 sites in United States, Argentina and 25 more
- Volunteers
- 629 people
- Sponsor
- Janssen Research & Development, LLC
Tumors
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended phase 2 dose; and to learn more about the…
- Trial name
- NCT00292864
- Testing
- SNS-032 Injection
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sunesis Pharmaceuticals
Advanced or Metastatic Urothelium Cancer
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or…
- Trial name
- NCT05754853
- Testing
- MRG002, Docetaxel Injection, Paclitaxel Injection
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Shanghai Miracogen Inc.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Esophageal Squamous Cell Carcinoma
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
Tislelizumab combined with chemotherapy sequential neoadjuvant therapy for non-cCR patients after neoadjuvant chemoradiotherapy in locally advanced ESCC.
- Trial name
- ETNT (NCT05189730)
- Testing
- Tirelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Upper Tract Urothelial Carcinoma
HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study
This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for…
- Trial name
- NCT06798246
- Testing
- Chemotherapy, Immunotherapy, ADC
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Triple Negative Breast Cancer
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
The purpose of this study is to evaluate the efficacy of SKB264 in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care
- Trial name
- NCT05347134
- Testing
- SKB264
- Where
- 2 sites in China
- Volunteers
- 254 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple-Negative Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer…
- Trial name
- NCT06382142
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced or Metastatic Breast Cancer
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer.
- Trial name
- NCT06105632
- Testing
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus
- Where
- 48 sites in United States, Argentina and 12 more
- Volunteers
- 333 people
- Sponsor
- Pfizer
Triple Negative Breast Cancer (TNBC)
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC.
- Trial name
- NCT03742349
- Testing
- spartalizumab, LAG525, NIR178
- Where
- 13 sites in United States, Australia and 7 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors, Melanoma
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
- Trial name
- NCT04172454
- Testing
- AK104
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
The main purpose of this study was to assess the safety, tolerability, and efficacy when combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted in 2 phases, Phase Ib and Phase II.
- Trial name
- NCT04856774
- Testing
- SHR-1701；BP102
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.